Current knowledge, describing the role of CUGBP1 protein in DM1 and CDM1 pathogenesis, suggests that CUGBP1 activity might be corrected in DM1 with the inhibitors of GSK3 kinase. This evidence concerns the gene CELF1 and myotonic dystrophy type 1.